Tagged with

EDBI/Bio One Capital As the CEO of EDBI since late 2008, what would you say have been the main developments of the agency during this time? EDBI is the strategic corporate investment arm of the Singapore Economic Development Board (EDB) and we invest in very select industry sectors. Investments in the Biomedical Sciences…

Dx assays Nine months ago you were appointed CEO of the company. What brought you to Dx assays? I think Dx Assays is a very interesting opportunity, which is why I came here. It is unusual in that it is not a traditional start-up diagnostics company. We are a company that carries…

ASLAN pharmaceuticals Why did you decide to start your own company? I started my career as a scientist with a real passion for molecular biology, and moved into pharmaceutical R&D working for AstraZeneca. After five or so years I was very keen to get commercial exposure, to see how we actually access…

Takeda Global Research & Development Center (Asia) What is the global R&D vision of Takeda, Japan’s largest pharmaceutical company that recently celebrated its 230th birthday? Takeda’s global R&D vision is committed to the discovery and development of innovative solutions that addresses unmet medical needs of patients. What distinguishes our R&D vision is an emphasis on innovation and…

Alandra Medical México Before we get into the company’s activities and market, could you give us a brief rundown of your past working experience prior to Alandra Medical? My experience outside of the United States is extensive, since I had been work-ing for Intel Corp. for more than twenty years and lived in…

Would you begin by outlining the key milestones & achievements of the NHMRC in the past four years? The first point is the development of our initiatives on an international level: for example, we joined the International Cancer Genome Consortium and we are funding pancreatic cancer and ovarian cancer both…

Lilly has invested over one billion EUR in its Kinsale site to date—including a recent 330 million EUR expansion that positions Ireland as a key location for Lilly’s biotech pipeline. How has this operation developed over time?  Eli Lilly first invested in Ireland in 1980. The company initially developed a…

Boehringer Ingelheim Austria Austria has always been a strategic market for the group: it has played a key role in Boehringer Ingelheim’s success story, as this is where the company established its first foreign subsidiary in 1948. Can you give our readers a snapshot of the strategic importance Austria has today for the…

Teva Ratiopharm Austria Dr Spatz, what would you highlight as the main specificities of the Austrian generic market, and explain how Teva has adapted its approach to the Austrian environment? Teva recently changed directions in its development, determined to be a multifaceted company, offering to the market not only generics but also branded…

Business & Decision Life Sciences Business & Decision Life Science was founded back in 2007, although that department existed within the group’s structure long before that. Could you highlight the reasons why a special business unit dedicated to the life sciences industry needed to be created back in 2007? Founded in 1992, Business & Decisions…

Sanofi - Belgium Mr Hendrickx, considering that you have been with Sanofi for over a decade, what would you describe as the single most important change in Sanofi’s business model? In essence, it is the diversification of Sanofi into a wide range of business activities. In the past, Sanofi was very successful at…

Menarini Austria Dr. Nikitsch, you started Menarini’s Austrian operations almost 13 years ago. Would you say that Menarini’s presence in Austria today reflects the vision you had for the company in Austria at its creation? I would go beyond this statement and say that Menarini Austria is more today than we expected…